Navigation Links
MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
Date:10/29/2008

VALENCIA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2008 third quarter financial results on Wednesday, November 5, 2008 at 8:00 a.m. EST.

Management of the Company will host a conference call to discuss the third quarter financial results, clinical progress and other Company developments at 9:00 a.m. EST on November 5, 2008. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (866) 411-1707 or (202) 369-0654. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA(TM), which has completed Phase 3 clinical trials, and MKC253, which is c
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
2. MannKind to Present at the UBS Global Life Sciences Conference
3. MannKind Corporation Reports Second Quarter Financial Results
4. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
5. MannKind to Present at Upcoming Conferences
6. MannKind Corporation Reports First Quarter Financial Results
7. MannKind to Present at the Morgan Stanley Healthcare Conference
8. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation Response to Recent Market Events
11. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... CA (PRWEB) , ... July 01, 2015 , ... It ... brain injury (TBI) using single photon emission computed tomography (SPECT) according to ... The study, which examined over 20,000 brain scans and is believed to be the ...
(Date:7/1/2015)... PARK, N.C. and PARIS ... research firm AgBiome, and Genective, key developer of ... accelerate the discovery of new generations of insect ... for insect control to counter the realities of ... with Genective, aligning AgBiome,s unique insect control technology ...
(Date:7/1/2015)... , July 1, 2015   Decision ... frequently cited advantages of Otezla are its oral ... profile, as reported by surveyed rheumatologists. Otezla was ... for the treatment of active psoriatic arthritis in ... current standard of care includes conventional oral treatments ...
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical market is ... the molecular diagnostics industry. BCC Research reveals in its new report that the market ... costs, and a growing need for better diagnostics as part of a molecular diagnostics ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4AgBiome and Genective collaborate to create novel insect-resistant crops 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3
... /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a ... of technologies targeting the chronic inflammation,underlying cardiovascular and ... CEO, will present a Company Overview at BIO,CEO ... York City, at 11:00,a.m. (ET) on Tuesday, February ...
... Feb. 5 EntreMed, Inc.,(Nasdaq: ENMD ) ... of cancer and inflammatory diseases, today,announced that James ... a Corporate overview at the BIO CEO and ... February 11-13, 2008. Mr. Burns,presentation is scheduled for ...
... to Advise on Development of New Drug ... Candidate to Treat Autoimmune Disease -, SAN ... development company, announced today that it,has appointed the first five ... protein licensed from Amgen in December 2007 for,the treatment of ...
Cached Biology Technology:Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 2Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 3EntreMed to Present at BIO CEO and Investor Conference 2Anthera Pharmaceuticals Forms Scientific Advisory Board 2
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... between researchers at the Hebrew university of Jerusalem and ... treatment of brain diseases. The researchers found that TyrNovo,s ... process of aging in order to protect the brain ... first and important step towards the development of future ...
... two-thirds (65%) of Americans say it,s likely there ... ahead as Congress continues to debate deficit and ... opinion poll commissioned by Research!America and the American ... party affiliations: Democrats (66%), Republicans (65%) and Independents ...
... and environmental organisations are working together to influence future ... English Channel is used daily by more than 500 ... shores in Southern England and Northern France, and it ... Now 12 organisations, led by Plymouth University, have ...
Cached Biology News:New compound for slowing the aging process can lead to novel treatments for brain diseases 2New compound for slowing the aging process can lead to novel treatments for brain diseases 3Majority of Americans believe another government shutdown likely in coming months 2Majority of Americans believe another government shutdown likely in coming months 3Anglo-French partnership develops guidance on future management of English Channel 2
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
IC50: 3 ng/ml · Limit of detection: 0.9 ng/ml...
Biology Products: